These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25201268)

  • 1. Electrochemical evaluation of Abelson tyrosine-protein kinase 1 activity and inhibition by imatinib mesylate and danusertib.
    Diculescu VC; Enache TA
    Anal Chim Acta; 2014 Oct; 845():23-9. PubMed ID: 25201268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an indirect pulsed electrochemical detection method for monitoring the inhibition of Abl1 tyrosine kinase.
    Chen H; Wang X; Chopra S; Adams E; Van Schepdael A
    J Pharm Biomed Anal; 2014 Mar; 90():52-7. PubMed ID: 24333704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of Abl1 tyrosine kinase inhibitors by liquid chromatography-electrospray ionization-mass spectrometry.
    Chen H; Adams E; Van Schepdael A
    Talanta; 2013 Mar; 107():88-94. PubMed ID: 23598197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The background, discovery and clinical development of BCR-ABL inhibitors.
    Lambert GK; Duhme-Klair AK; Morgan T; Ramjee MK
    Drug Discov Today; 2013 Oct; 18(19-20):992-1000. PubMed ID: 23769978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
    Vajpai N; Strauss A; Fendrich G; Cowan-Jacob SW; Manley PW; Jahnke W; Grzesiek S
    Biomol NMR Assign; 2008 Jun; 2(1):41-2. PubMed ID: 19636920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
    Park J; Kim S; Oh C; Yoon SS; Lee D; Kim Y
    Biochem Biophys Res Commun; 2005 Oct; 336(3):942-51. PubMed ID: 16157305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
    De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
    Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New effective inhibitors of the Abelson kinase.
    Kraus GA; Gupta V; Mokhtarian M; Mehanovic S; Nilsen-Hamilton M
    Bioorg Med Chem; 2010 Sep; 18(17):6316-21. PubMed ID: 20674368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
    Tomita O; Iijima K; Ishibashi T; Osumi T; Kobayashi K; Okita H; Saito M; Mori T; Shimizu T; Kiyokawa N
    Leuk Res; 2014 Mar; 38(3):361-70. PubMed ID: 24367893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
    Lupino E; Ramondetti C; Buccinnà B; Piccinini M
    Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
    Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
    Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
    Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
    Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
    Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.